ProPhase Labs, Inc. (PRPH)
NASDAQ: PRPH · Real-Time Price · USD
0.3670
+0.0242 (7.06%)
At close: Jun 27, 2025, 4:00 PM
0.3760
+0.0090 (2.45%)
After-hours: Jun 27, 2025, 6:39 PM EDT
ProPhase Labs Revenue
ProPhase Labs had revenue of $1.43M in the quarter ending March 31, 2025, a decrease of -39.26%. This brings the company's revenue in the last twelve months to $5.85M, down -67.59% year-over-year. In the year 2024, ProPhase Labs had annual revenue of $6.77M, down -80.65%.
Revenue (ttm)
$5.85M
Revenue Growth
-67.59%
P/S Ratio
1.55
Revenue / Employee
$60,885
Employees
96
Market Cap
15.25M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6.77M | -28.21M | -80.65% |
Dec 31, 2023 | 34.98M | -87.66M | -71.48% |
Dec 31, 2022 | 122.65M | 43.61M | 55.17% |
Dec 31, 2021 | 79.04M | 64.53M | 444.59% |
Dec 31, 2020 | 14.51M | 4.64M | 46.96% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PRPH News
- 2 days ago - ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule - GlobeNewsWire
- 11 days ago - ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer - GlobeNewsWire
- 22 days ago - ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform - GlobeNewsWire
- 5 weeks ago - ProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025 - GlobeNewsWire
- 6 weeks ago - ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025 - GlobeNewsWire
- 3 months ago - ProPhase Labs, Inc. (PRPH) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024 - GlobeNewsWire